GlycoEra AG

Biotechnology ResearchZurich, Switzerland11-50 Employees

GlycoEra is developing biologics to selectively target the root cause of many autoimmune diseases: a specific circulating protein (autoantibody). Our approach enables us to degrade targets rapidly, selectively, and deeply while avoiding broader dampening of the immune system. This offers many potential benefits over existing broad-spectrum immune-suppressing therapies, including an improved safety profile and the potential for earlier disease intervention – which could improve patient quality of life, limit long-term complications and lower overall healthcare costs.

Our best-in-class, extracellular degrader BiND™ platform (Biologic Natural Degrader), allows us to target and rapidly, deeply degrade any circulating protein of interest regardless of therapeutic area – such as an autoantibody in autoimmune disease, a circulating factor inducing inflammation or a protein aggregate in neurological disease.

Sign up for free to view info

Email Format Employee directory